Scott's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2024
Question
Scott asked about the post-combination synergies, specifically how the combined data and platforms of Recursion and Exscientia would benefit existing and future programs.
Answer
David Hallett, Interim CEO of Exscientia, explained that combining the vast data sets from both companies creates a powerful learning organization that will benefit current and future partners as well as the internal pipeline. Najat Khan, Chief R&D and Commercial Officer, added a specific example, noting that Recursion's capabilities in patient stratification, such as through its Tempus partnership, could be applied to Exscientia's programs like CDK7 to improve trial design and effectiveness.